Enrollment is complete for two pivotal phase 3 studies of intravitreal pegcetacoplan, a targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.
The DERBY and OAKS studies will include 1,259 patients. The randomized studies will evaluate the efficacy and safety of intravitreal pegcetacoplan (APL-2) compared with sham treatment, according to a press release from Apellis Pharmaceuticals.
The primary outcome for each study will be the reduction in growth of geographic atrophy lesion size, which will be measured by fundus autofluorescence at month
Uncategorized